Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. HER2 compound I-4
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. HER2 compound I-4: sourced facts only. name: "The binding affinity assay and confocal analysis revealed that I-1 and I-4 were effective at targeting HER2." [PMID:36351049]; target: "The binding affinity assay and confocal analysis revealed that I-1 and I-4 were effective at targeting HER2." [PMID:36351049]; developer: "Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China." [PMID:36351049]; stage: "Moreover, I-1 and I-4 showed better stability than single targeting peptide and presented enhanced antitumor activity and safety than CPT in tumor-bearing mice." [PMID:36351049]
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on China Pharma Univ. HER2 compound I-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. HER2 compound I-4.